Europe Gastrointestinal Drugs Companies
General overview of the pharmaceutical industry in Europe, the Middle East, and Africa (EMEA) with a focus on gastrointestinal drugs.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Europe, the Middle East and Africa Gastrointestinal Drugs Companies Update
October 2023: Self-insured companies and plan sponsors around the country planned to take advantage of Parsley Health's gastrointestinal program, a digital health initiative aimed at reducing expenses in patients with complicated and chronic diseases through the use of root cause medicine. Employers may save money with this innovative benefit, which targets the roughly 50% of women and 37% of men who have at least one gastrointestinal issue. For both sexes combined, the direct cost of treating gastrointestinal conditions is over $135 billion per year, placing it in the top five expense categories for businesses. Autoimmunity, hormone balance, and mental health are all impacted by gastrointestinal disorders. Their most recent poll of working women confirmed that this is a major reason why women miss time in the office. Intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), Crohn's disease (CD), and other gastrointestinal disorders are all covered extensively in the curriculum.
July 2022: The launch of the blockbuster biologic medication Vedolizumab in India was announced by Takeda India, a division of the Japanese pharmaceutical firm Takeda Pharmaceutical Company. The drug is part of the Gastrointestinal (GI) portfolio. Haematology, Genetic Diseases, and Immunology is Takeda's first therapeutic area in India, whereas GI is their second. For the treatment of chronic inflammatory bowel illnesses (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD), vedolizumab will be offered in India under the brand name Kynteles. Kynteles has demonstrated positive safety and effectiveness outcomes in the treatment of individuals with moderate to severe inflammatory bowel disease (IBD), according to the business. The business did not reveal the pricing, but they did say it will be priced with the Indian market's affordability and accessibility in mind.List of Europe, the Middle East and Africa Gastrointestinal Drugs Key companies in the market
- AstraZeneca Plc.(UK)
- Johnson & Johnson (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Valeant Pharmaceuticals Inc. (US)
- Sanofi Ltd. (France)
- Valeant (US)
- Abbott Laboratories(US)
- Allergan Plc (US)
- Bayer AG (Germany)
- Janssen Biotech Inc. (US)
- AbbVie Inc. (US)
- Janssen Biotech (US)
- GlaxoSmithKline Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
Europe Gastrointestinal Drugs Market Highlights:
Europe Gastrointestinal Drugs Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
